Standardized modulation of the injection site allows for insulin dose reduction without deterioration of metabolic control

Current Medical Research and Opinion

Volumn 30, Issue 10, 2014, Pages 2001-2008

  Pfützner, Andreas ^a   Dissel, S ^b   Forkel, C ^c   Grenningloh, M ^c   Bitton, G ^d   Nagar, R ^d   Forst, T ^b  

^a Diabetes Center and Practice   (Germany)

^b Profil Mainz   (Germany)

^c ClinLogix Europe   (Germany)

^d Insuline Medical   (Israel)

Author keywords

Injection site modulation device; Insulin absorption; Meal tolerance test; Prandial insulin dose

Indexed keywords

3 NITROTYROSINE; ARGININE; C PEPTIDE; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; N(G),N(G) DIMETHYLARGININE; PROINSULIN; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DRUG DELIVERY DEVICE; DRUG DOSE REDUCTION; ENDOCRINE FUNCTION TEST; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INJECTION SITE; INJECTION SITE MODULATION DEVICE; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; RANDOMIZED CONTROLLED TRIAL; TEST MEAL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG MONITORING; HYPOGLYCEMIA; METABOLISM; MIDDLE AGED; PROCEDURES; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG MONITORING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84925255979     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.933098     Document Type: Article

References (25)

1. Koivisto VA. Sauna-induced acceleration in insulin absorption from subcutaneous injection site. Br Med J 1980;280:1411-13
2. Sindelka G, Heinemann L, Berger M, et al. Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Diabetologia 1994;37:377-80
3. Magerl W, Treede RD. Heat-evoked vasodilatation in human hairy skin: axon reflexes due to low-level activity of nociceptive afferents. J Physiol 1996;497(Pt 3):837-48
4. Minson CT, Berry LT, Joyner MJ. Nitric oxide and neurally mediated regulation of skin blood flow during local heating. J Appl Physiol 2001;91:1619-26
5. Kellogg Jr DL. In vivo mechanisms of cutaneous vasodilation and vasoconstriction in humans during thermoregulatory challenges. J Appl Physiol 2006;100:1709-18
6. Raz I, Weiss R, Yegorchikov Y, et al. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. Clin Ther 2009;31:980-7
7. Raz I, Yegorchikov Y, Bitton G, et al. Improving pharmacokinetic and pharmacodynamic profiles of rapid-acting insulin analogs using the InsuPatch device. J Diabetes Sci Technol 2009;3:384.A138
8. Bitton G, Raz I, Pfützner A, et al. Reduced postprandial glucose excursion in type 2 diabetic subjects using the InsuPad device. Diabetologia 2012;55(Suppl 1):A98
9. Pfützner A, Feldman D, Bitton G, et al. Effect of the InsuPad device on post-prandial glucose excursion in type II diabetic subjects. Diabetes Technol Ther 2013;15(Suppl 1):A167
10. Freckmann G, Pleus S, Haug A, et al. Increasing local blood flow by warming the application site: beneficial effects on postprandial glycemic excursions. J Diabetes Sci Technol 2012;6:780-5
11. Pfützner A, Hermanns N, Funke K, et al. The BARMER-Study: standardized warming of the injection site to enhance insulin absorption and reduce prandial insulin requirements and hypoglycemia frequency under daily life conditions. Curr Med Res Opin 2013;30:753-60
12. Turnheim K, Waldhäusl WK. Essentials of insulin pharmacokinetics. Wien Klin Wochenschr 1988;100:65-72
13. Luzi L, DeFronzo RA. Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. Am J Physiol 1989;257:E241-6
14. Sindelar DK, Balcom JH, Chu CA, et al. A comparison of the effects of selective increases in peripheral or portal insulin on hepatic glucose production in the conscious dog. Diabetes 1996;45:1594-604
15. Lewis GF, Zinman B, Groenewoud Y, et al. Hepatic glucose production is regulated both by direct hepatic and extrahepatic effects of insulin in humans. Diabetes 1996;45:454-62
16. Bruttomesso D, Pianta A, Mari A, et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 1999;48:99-105
17. Edgerton DS, Lautz M, Scott M, et al. Insulin's direct effects on the liver dominate the control of hepatic glucose production. J Clin Invest 2006;116:521-7
18. Koivisto VA. The human insulin analogue insulin lispro. Ann Med 1998;30:260-6
19. Schade DS, Duckworth WC. In search of the subcutaneous-insulin-resistance syndrome. N Engl J Med 1986;315:147-53
20. Jakobsen LA, Jensen A, Larsen LE, et al. Effect of cutaneous blood flow on absorption of insulin: a methodological study in healthy male volunteers. Int J Physiol Pathophysiol Pharmacol 2011;3:257-65
21. Forst T, Hohberg C, Pfützner A. Cardiovascular effects of disturbed insulin activity in metabolic syndrome and in type 2 diabetic patients. Horm Metab Res 2009;41:123-31
22. Rask-Madsen C, Kahn CR. Tissue-specific insulin signaling, metabolic syndrome, and cardiovascular disease. Arterioscler Thromb Vasc Biol 2012;32:2052-9
23. Forst T, Pfützner A, Flacke F, et al. Postprandial vascular effects of VIAject compared with insulin lispro and regular human insulin in patients with type 2 diabetes. Diabetes Care 2010;33:116-20
24. Hohberg C, Forst T, Larbig M, et al. Effect of insulin glulisine on microvascular blood flow and endothelial function in the postprandial state. Diabetes Care 2008;31:1021-5
25. Pfützner A, Weise A, Pfützner E, et al. Influence of VIAject absorption kinetics on postreceptor signal transduction and vascular function of insulin in patients with type 2 diabetes. J Diabetes Sci Technol 2010;4:A128